MLH1 Antibody (D-2): sc-166625

MLH1 Antibody (D-2) is a mouse monoclonal IgG1 antibody that detects MLH1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MLH1 plays a crucial role in the DNA mismatch repair (MMR) pathway, which is vital for maintaining genetic stability by correcting errors that occur during DNA replication. MLH1 (D-2) antibody enables detection of deficiencies that can lead to microsatellite instability and an increased risk of various cancers, including hereditary nonpolyposis colorectal cancer (HNPCC). MLH1 is predominantly located in the nucleus, where MLH1 forms a complex with other MMR proteins to identify and repair mismatched DNA bases. This localization allows for immediate response to DNA damage, thereby preventing the accumulation of mutations that could lead to tumorigenesis. Loss of MLH1 expression is often associated with a mutated phenotype in tumors, highlighting MLH1′s importance as a biomarker for cancer diagnosis and prognosis. Anti-MLH1 antibody (D-2) is particularly valuable for researchers studying the implications of MMR deficiencies in cancer biology and therapeutic responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MLH1 Antibody (D-2) References:

1. HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1.  |  Raevaara, TE., et al. 2004. Genes Chromosomes Cancer. 40: 261-5. PMID: 15139004
2. Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer.  |  Niv, Y. 2007. World J Gastroenterol. 13: 1767-9. PMID: 17465465
3. Expression and promoter DNA methylation of MLH1 in colorectal cancer and lung cancer.  |  Ma, Y., et al. 2017. Pathol Res Pract. 213: 333-338. PMID: 28214209
4. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.  |  Hinrichsen, I., et al. 2017. Mol Carcinog. 56: 1816-1824. PMID: 28224663
5. Enhanced Tumoral MLH1-Expression in MLH1-/PMS2-Deficient Colon Cancer Is Indicative of Sporadic Colon Cancer and Not HNPCC.  |  Tarancón-Diez, M., et al. 2020. Pathol Oncol Res. 26: 1435-1439. PMID: 30613919
6. Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer.  |  Wang, SM., et al. 2019. World J Gastrointest Oncol. 11: 1065-1080. PMID: 31798786
7. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.  |  Kurpiel, B., et al. 2022. Int J Gynecol Pathol. 41: 1-11. PMID: 33577226
8. Mlh1 heterozygosity and promoter methylation associates with microsatellite instability in mouse sperm.  |  Shrestha, KS., et al. 2021. Mutagenesis. 36: 237-244. PMID: 33740045
9. The unstructured linker of Mlh1 contains a motif required for endonuclease function which is mutated in cancers.  |  Torres, KA., et al. 2022. Proc Natl Acad Sci U S A. 119: e2212870119. PMID: 36215471
10. Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 'Lynch-like' mismatch repair gene mutation.  |  Toboni, MD., et al. 2023. Gynecol Oncol. 177: 132-141. PMID: 37683549

The preferred MLH1 antibody is MLH1 Antibody (B-12): sc-271978.